April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
NFkB Inhibition in Uveal Melanoma - construction of a new delivery system
Author Affiliations & Notes
  • Shahar Frenkel
    Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Dudi Shneor
    Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    Biochemistry and Molecular Biology, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
  • Alik Honigman
    Biochemistry and Molecular Biology, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
  • Jacob Pe'er
    Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Footnotes
    Commercial Relationships Shahar Frenkel, None; Dudi Shneor, None; Alik Honigman, None; Jacob Pe'er, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 846. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shahar Frenkel, Dudi Shneor, Alik Honigman, Jacob Pe'er; NFkB Inhibition in Uveal Melanoma - construction of a new delivery system. Invest. Ophthalmol. Vis. Sci. 2014;55(13):846. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have previously shown that NFkB inhibition leads to diminished uveal melanoma cell viability in vitro, and to necrosis of tumors in vivo in the mouse intrahepatic direct injection model. Here we describe the design of a targeted delivery system which affects only dividing cells - a recombinant Murine leukemia virus (MuLV)-based replication-competent retroviruses (RCR) delivery system.

Methods: We exchanged the GFP sequence in the IRES-GFP cassette of the MuLV-based RCR pACE with the NFkB nuclear localization sequence VQRKRQKLMP (pACE-NFkB-NLS). Five uveal melanoma cell lines were infected with the pACE-NFkB-NLS vector. Infected cells were grown on “chamber-slides” without or with the TNFα activator of NFkB, and the subcellular localization of NFkB was analyzed with a laser scanning confocal microscope (Nikon). Activity of NFkB was analyzed by transfecting infected cell with a luciferase based reporter gene. Cell viability and caspase 3 activity were determined using the Fluorescent Cell Viability and Caspase-Glo 3/7 Assays (Promega).

Results: Expression of the NLS peptide inside the cells created a competition with the activated NFkB, and reduced its nuclear localization and its ability to trans-activate target genes.

Conclusions: Inhibition of NFkB reduces cell viability and increases apoptosis. This new modality for NFkB inhibition which can spread through solid tumors is expected to better affect tumors in vivo than IV/IP administration of chemotherapeutics.

Keywords: 589 melanoma • 744 tumors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×